Arribas López, José R <br/><br/>
[Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].  [electronic resource] 

 -  Enfermedades infecciosas y microbiologia clinica  Oct 2008 
 - 23-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>0213-005X 
<br/><br/><label>Standard No.: </label>10.1016/s0213-005x(08)76560-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Benzoates--adverse effects<br/>CCR5 Receptor Antagonists<br/>Chemical and Drug Induced Liver Injury--etiology<br/>Clinical Trials as Topic--statistics & numerical data<br/>Comorbidity<br/>Cyclohexanes--adverse effects<br/>Diketopiperazines<br/>Disease Susceptibility<br/>Drug Design<br/>HIV Fusion Inhibitors--adverse effects<br/>HIV Infections--drug therapy<br/>Homozygote<br/>Humans<br/>Hyperlipidemias--epidemiology<br/>Incidence<br/>Infections--epidemiology<br/>Maraviroc<br/>Membrane Fusion--drug effects<br/>Neoplasms--epidemiology<br/>Piperazines--adverse effects<br/>Receptors, CCR5--genetics<br/>Sequence Deletion<br/>Spiro Compounds--adverse effects<br/>Triazoles--adverse effects<br/>Virus Attachment--drug effects<br/>Virus Internalization--drug effects<br/>env Gene Products, Human Immunodeficiency Virus--physiology